These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 6771091)
1. Use of low-dosage oral cyproterone acetate as a male contraceptive. Wang C; Yeung KK Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091 [TBL] [Abstract][Full Text] [Related]
2. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Moltz L; Römmler A; Post K; Schwartz U; Hammerstein J Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095 [TBL] [Abstract][Full Text] [Related]
3. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Soufir JC; Jouannet P; Marson J; Soumah A Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496 [TBL] [Abstract][Full Text] [Related]
4. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Guerin JF; Rollet J Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439 [TBL] [Abstract][Full Text] [Related]
6. Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers. Koch UJ; Lorenz F; Danehl K; Ericsson R; Hasan SH; Keyserlingk DV; Lübke K; Mehring M; Römmler A; Schwartz U; Hammerstein J Contraception; 1976 Aug; 14(2):117-35. PubMed ID: 949890 [TBL] [Abstract][Full Text] [Related]
7. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. Wallace EM; Gow SM; Wu FC J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955 [TBL] [Abstract][Full Text] [Related]
8. Studies with cyproterone acetate for male contraception. Roy S; Chatterjee S J Steroid Biochem; 1979 Jul; 11(1B):675-80. PubMed ID: 491632 [TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men. Foegh M; Nicol K; Petersen IB; Schou G Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869 [TBL] [Abstract][Full Text] [Related]
10. The influence of pharmaceutical compounds on male fertility. Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I Andrologia; 1976; 8(3):203-35. PubMed ID: 793446 [TBL] [Abstract][Full Text] [Related]
11. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. Matsumoto AM J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626 [TBL] [Abstract][Full Text] [Related]
12. The effects of low doses of cyproterone acetate on some functions of the reproductive system in normal men. Føgh M; Corker CS; Hunter WM; McLean H; Philip J; Schou G; Skakkebaek NE Acta Endocrinol (Copenh); 1979 Jul; 91(3):545-52. PubMed ID: 474042 [TBL] [Abstract][Full Text] [Related]
13. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868 [TBL] [Abstract][Full Text] [Related]
14. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869 [TBL] [Abstract][Full Text] [Related]
15. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme. Bain J; Rachlis V; Robert E; Khait Z Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093 [TBL] [Abstract][Full Text] [Related]
16. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. Behre HM; Nashan D; Hubert W; Nieschlag E J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833 [TBL] [Abstract][Full Text] [Related]
17. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300 [TBL] [Abstract][Full Text] [Related]
18. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception. Knuth UA; Yeung CH; Nieschlag E Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404 [TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Falsetti L; Galbignani E Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631 [TBL] [Abstract][Full Text] [Related]
20. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human. Kumari GI; Das RP; Madoiya KK; Jain AK; Roy S Fertil Steril; 1977 Nov; 28(11):1168-74. PubMed ID: 562781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]